About us

About us

What we offer

esqLABS is a competent service partner to support decision making processes at various mile-stones along the entire life cycle of pharmaceutical products from research through development and at the point of care.

Pharma R&D

Specialty Patient Care

We help increase efficiency (reduce time and cost) by integration of R&D data within our modeling & simulation frameworks to

  • build knowledge and improve understanding
    of drug & disease
  • deliver informed input for Go/NoGo decisions

We leverage R&D knowledge within our modeling & simulation frameworks to

  • improve dosing to efficiently and safely reach the personalized treatment goal
  • increase quality of care by reducing drug adverse events, and follow up costs
E

Pharma R&D

We help increase efficiency (reduce time and cost) by integration of R&D data within our modeling & simulation frameworks to

  • build knowledge and improve understanding of drug & disease
  • deliver informed input for Go/NoGo decisions
C

Specialty Patient Care

We leverage R&D knowledge within our modeling & simulation frameworks to

  • improve dosing to efficiently and safely reach the personalized treatment goal
  • increase quality of care by reducing drug adverse events, and follow up costs

How we work

esqLABS is commited to deliver the quality our customers expect.
We utilize:

    • validated computational tools
    • scripted workflows for full reproducability of our results
    • and thorough documentation of our model development processes

Powered by


Our platforms are developed with the free-to-use software tool Open-Systems-Pharmacology Suite consisting of PK-Sim® and MoBi®, which is capable of integrating biological knowledge and prior data for building and simulating models that integrate across (all) biological scales.  

Meet the Team

Stephan Schaller

PhD, Dipl.- Ing.

Founder, CEO and Senior Consultant
Systems Pharmacologist
& -Engineer

Pavel Balazki

MSc. Bioinformatics

Consultant and PB-QSP Platform Developer
Systems Pharmacologist
& Bioinformatician

Stephan Schaller

PhD, Dipl.- Ing.

Founder, CEO and Senior Consultant
Systems Pharmacologist
& -Engineer

About Stephan Schaller

Stephan Schaller is a Systems Scientist passionate about Model Based Drug Discovery, Development and Dosing (MI4D) with over eight years of industry experience. His experience ranges from target validation in the early phases of drug discovery to development of automated decision support systems for drug dosing at the point of care.

Stephan Schaller founded esqLABS GmbH to advance the integration of computational methods in healthcare to derive effective computational platforms for drug-, device- and treatment-development and -optimization (i.e. personalization).

During his time in industry, he has leveraged physiologically-based concepts for decision-making support to drug discovery and development teams in various therapeutic areas, including oncology, immunology, hematology, cardiovascular and metabolic disease.

Stephan Schaller studied Control Systems Engineering and Systems Biology at the University of Stuttgart, Germany and received his PhD from the RWTH Aachen University, Germany in collaboration with Bayer in Computational Engineering for the development of an automated decision support system for insulin dosing in type 1 diabetes patients.

List of Publications:

Peer Reviewed Journal Articles

Schaller S, et al.: A New Perspective on Closed-Loop Glucose Control Using a Physiology Based Pharmacokinetic / Pharmacodynamic Model Kernel. IFAC Paper, 8th IFAC Symposium on Biological and Medical Systems, 2012; doi:10.3182/20120829-3-HU-2029.00111

Krauss M, Schaller S, et al.: Integrating cellular metabolism into a multiscale whole-body model.  PLoS computational biology 8: e1002750.

Schaller S, et al.: A generic integrated physiologically-based whole-body model of the glucose-insulin-glucagon regulatory system. CPT: PSP 2013.

Schaller S, et al.: Robust MPC of blood glucose using generic whole-body physiology-based PK/PD model kernels. IEEE Transactions in Biomedical Engineering, 2015.

Wadehn F, Schaller S, et al.: A multiscale, model-based analysis of the multi-tissue interplay underlying blood glucose regulation in diabetes. EMBC 2016.

Lahoz-Beneytez J, Schaller S, et al.: Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans. Frontiers in Immunology, 2017.

Schaller S, et al.: Blood glucose control in T1DM subjects- prospects for generic whole-body physiology-based PK/PD model kernels: Clinical Trial and Post-Hoc Study. In internal revision 2018.

Book Chapters

Lippert J. et al. (2015) Modeling and Simulation of In Vivo Drug Effects. In: Nielsch U., Fuhrmann U., Jaroch S. (eds) New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, vol 232. Springer, Cham

Conference Talks

Schaller S, Eissing T, et al.:  A physiologically-based PK/PD model to capture population variability for diabetes research and automatic blood glucose control. PAGE Meeting, Venice, June 6, 2012

Schaller S, et al.: A New Perspective on Closed-Loop Glucose Control Using a Physiology-Based Pharmacokinetic / Pharmacodynamic Model Kernel. 8th IFAC Symposium on Biological and Medical Systems, Budapest, Hungary, 2012

Schaller S, Block M, et al.: The REACTION platform–Improving long-term Management of Diabetes-Personalized Diabetes Therapy and Automatic Blood Glucose Control. Medicine with SOA, Grid, and Cloud – transmed.infinity-3.de

Schaller S, et al.: Closed-Loop Insulin Delivery Using a Physiology-Based Pharmacokinetic / Pharmacodynamic Model Kernel. 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Paris, France, 2013

Barrett J, Schaller S: Exendin-(9-39) for Treating Children with Congenital Hyperinsulinism. ASCPT Annual Meeting, Atlanta, USA, 2014

Schaller S: Next Generation PB-PK/PD Modeling: Beyond Small Molecules: PBPK of Biological Therapeutic. ASCPT Annual Meeting, New Orleans, USA, 2015

Schaller S: PB-PK/PD Modeling Beyond Small Molecules: A PBPK/PD Model of Glucose Homeostasis. ISSX, Cologne, Germany, 2017

Conference Posters

Presented multiple posters at different conferences (amongst others at ATTD 2012/13, LACDR Meeting 2014, PAGE 2014, ACoP 2014, ICSB 2016, PAGE 2017, PAGE 2018)

Pavel Balazki

MSc. Bioinformatics

Consultant and PB-QSP Platform Developer
Systems Pharmacologist
& Bioinformatician

About Pavel Balazki

Pavel is an interdisciplinary scientist with a solid experience in physiological modeling and programming skills. He focuses on the combination of modeling and software development to offer QSP platforms as integrated solutions.

Before joining esqLABS, Pavel acquired strong knowledge and expertise in mechanistic and physiologically based PK/PD modeling, biology, and human physiology. He has developed software tools for stochastic simulations of biological systems and graph database-based text analysis.

Pavel studied bioinformatics at the Goethe University in Frankfurt and completed his master’s thesis at Sanofi, where he was working on mechanistic modeling of diabetes. He then joined the Systems Pharmacology group at Bayer to work on his PhD thesis in collaboration with Professor Thorsten Lehr from the Clinical Pharmacy department of the University of Saarland.

List of Publications:

Balazki, P., Eissing, T., and Lehr, T. Physiologically-based pharmacokinetics/pharmacodynamics (PBPK/PD) systems pharmacology model of glucose homeostasis in human. Annual meeting of the German Pharmaceutical Society (DPhG) 2017, Saarbruecken, Germany

Balazki, P., Woerle, V., Schaller, S., Eissing, T., and Lehr, T. Physiologically-based Pharmacokinetics/Pharmacodynamics model of dapagliflozin, an oral SGLT2 inhibitor. Population Approach Group Europe (PAGE) meeting 2017, Budapest, Hungary

Balazki, P., Lindauer, K., Einloft, J., Ackermann, J., and Koch, I. MONALISA for stochastic simulations of Petri net models of biochemical systems. BMC Bioinformatics (2015) 16: 371

About Stephan Schaller

Stephan Schaller is a Systems Scientist passionate about Model Based Drug Discovery, Development and Dosing (MI4D) with over eight years of industry experience. His experience ranges from target validation in the early phases of drug discovery to development of automated decision support systems for drug dosing at the point of care.

Stephan Schaller founded esqLABS GmbH to advance the integration of computational methods in healthcare to derive effective computational platforms for drug-, device- and treatment-development and -optimization (i.e. personalization).

During his time in industry, he has leveraged physiologically-based concepts for decision-making support to drug discovery and development teams in various therapeutic areas, including oncology, immunology, hematology, cardiovascular and metabolic disease.

Stephan Schaller studied Control Systems Engineering and Systems Biology at the University of Stuttgart, Germany and received his PhD from the RWTH Aachen University, Germany in collaboration with Bayer in Computational Engineering for the development of an automated decision support system for insulin dosing in type 1 diabetes patients.

List of Publications:

Peer Reviewed Journal Articles

Schaller S, et al.: A New Perspective on Closed-Loop Glucose Control Using a Physiology Based Pharmacokinetic / Pharmacodynamic Model Kernel. IFAC Paper, 8th IFAC Symposium on Biological and Medical Systems, 2012; doi:10.3182/20120829-3-HU-2029.00111

Krauss M, Schaller S, et al.: Integrating cellular metabolism into a multiscale whole-body model.  PLoS computational biology 8: e1002750.

Schaller S, et al.: A generic integrated physiologically-based whole-body model of the glucose-insulin-glucagon regulatory system. CPT: PSP 2013.

Schaller S, et al.: Robust MPC of blood glucose using generic whole-body physiology-based PK/PD model kernels. IEEE Transactions in Biomedical Engineering, 2015.

Wadehn F, Schaller S, et al.: A multiscale, model-based analysis of the multi-tissue interplay underlying blood glucose regulation in diabetes. EMBC 2016.

Lahoz-Beneytez J, Schaller S, et al.: Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans. Frontiers in Immunology, 2017.

Schaller S, et al.: Blood glucose control in T1DM subjects- prospects for generic whole-body physiology-based PK/PD model kernels: Clinical Trial and Post-Hoc Study. In internal revision 2018.

Book Chapters

Lippert J. et al. (2015) Modeling and Simulation of In Vivo Drug Effects. In: Nielsch U., Fuhrmann U., Jaroch S. (eds) New Approaches to Drug Discovery. Handbook of Experimental Pharmacology, vol 232. Springer, Cham

Conference Talks

Schaller S, Eissing T, et al.:  A physiologically-based PK/PD model to capture population variability for diabetes research and automatic blood glucose control. PAGE Meeting, Venice, June 6, 2012

Schaller S, et al.: A New Perspective on Closed-Loop Glucose Control Using a Physiology-Based Pharmacokinetic / Pharmacodynamic Model Kernel. 8th IFAC Symposium on Biological and Medical Systems, Budapest, Hungary, 2012

Schaller S, Block M, et al.: The REACTION platform–Improving long-term Management of Diabetes-Personalized Diabetes Therapy and Automatic Blood Glucose Control. Medicine with SOA, Grid, and Cloud – transmed.infinity-3.de

Schaller S, et al.: Closed-Loop Insulin Delivery Using a Physiology-Based Pharmacokinetic / Pharmacodynamic Model Kernel. 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), Paris, France, 2013

Barrett J, Schaller S: Exendin-(9-39) for Treating Children with Congenital Hyperinsulinism. ASCPT Annual Meeting, Atlanta, USA, 2014

Schaller S: Next Generation PB-PK/PD Modeling: Beyond Small Molecules: PBPK of Biological Therapeutic. ASCPT Annual Meeting, New Orleans, USA, 2015

Schaller S: PB-PK/PD Modeling Beyond Small Molecules: A PBPK/PD Model of Glucose Homeostasis. ISSX, Cologne, Germany, 2017

Conference Posters

Presented multiple posters at different conferences (amongst others at ATTD 2012/13, LACDR Meeting 2014, PAGE 2014, ACoP 2014, ICSB 2016, PAGE 2017, PAGE 2018)

About Pavel Balazki

Pavel is an interdisciplinary scientist with a solid experience in physiological modeling and programming skills. He focuses on the combination of modeling and software development to offer QSP platforms as integrated solutions.

Before joining esqLABS, Pavel acquired strong knowledge and expertise in mechanistic and physiologically based PK/PD modeling, biology, and human physiology. He has developed software tools for stochastic simulations of biological systems and graph database-based text analysis.

Pavel studied bioinformatics at the Goethe University in Frankfurt and completed his master’s thesis at Sanofi, where he was working on mechanistic modeling of diabetes. He then joined the Systems Pharmacology group at Bayer to work on his PhD thesis in collaboration with Professor Thorsten Lehr from the Clinical Pharmacy department of the University of Saarland.

List of Publications:

Balazki, P., Eissing, T., and Lehr, T. Physiologically-based pharmacokinetics/pharmacodynamics (PBPK/PD) systems pharmacology model of glucose homeostasis in human. Annual meeting of the German Pharmaceutical Society (DPhG) 2017, Saarbruecken, Germany

Balazki, P., Woerle, V., Schaller, S., Eissing, T., and Lehr, T. Physiologically-based Pharmacokinetics/Pharmacodynamics model of dapagliflozin, an oral SGLT2 inhibitor. Population Approach Group Europe (PAGE) meeting 2017, Budapest, Hungary

Balazki, P., Lindauer, K., Einloft, J., Ackermann, J., and Koch, I. MONALISA for stochastic simulations of Petri net models of biochemical systems. BMC Bioinformatics (2015) 16: 371

Marco Albrecht

PhD Systems Biology

QSP Platform Developer
Bioengineer &
Systems Biologist

Kah-Tong Seow

PhD Bioinformatics

Lead Software Engineer
Software Developer C# / .Net
& Bioinformatician

Marco Albrecht

PhD Systems Biology

QSP Platform Developer
Bioengineer &
Systems Biologist

About Marco Albrecht

Marco Albrecht is a Biosystems Engineer, who is passionate about combining natural science disciplines with the power of mathematics.

He was interdisciplinary trained in molecular biology, system theory, control engineering, and modelling from the first semester at the Otto-von-Guericke University in Magdeburg.  Magdeburg is a European hub for bottom-up modelling and harbours the Max-Planck Institute for the Dynamic of Complex Technical Systems.

Marco Albrecht has not only worked in four different hospital wards at an early age but also in several high-tech life-science start-ups and research incubators such as GenDx in the Netherlands, Optimata in Israel and BioMed X in Heidelberg as well as in several research groups such as the experimental dermatology group at the TU Dresden and the porous media department at the University of Bordeaux.

His Master´s thesis at the University of Heidelberg was on identifying differentially expressed features in transcriptome dynamics, and his dissertation at the University of Luxembourg was on mathematical histopathology and systems pharmacology of melanoma. Marco Albrecht reached in all research projects the highest possible grades and was funded by the prestigious EU Marie Skłodowska-Curie research grant.

Marco Albrecht brings substantial experience in modelling tissue physiology, systems biology and analysing omics-data to esqLABS and will act as QSP-platform developer. His first project will be in precision medicine for patients in intensive care units.

List of Publications:

Peer Reviewed Journal Articles

Marco Albrecht, Giuseppe Sciume, Philippe Lucarelli, and Thomas Sauter. Thermodynamically constrained averaging theory for cancer growth modelling. IFAC-PapersOnLine, 49(26):289{294, 2016.

Marco Albrecht, Damian Stichel, Benedikt Muller, Ruth Merkle, Carsten Sticht, Norbert Gretz, Ursula Klingmuller, Kai Breuhahn, and Franziska Matthaus. TTCA: an R package for the identi cation of di erentially expressed genes in time course microarray data. BMC bioinformatics, 18(1):33, 2017.

Margarita Gonzalez-Vallinas, Manuel Rodriguez-Paredes, Marco Albrecht, Carsten Sticht, Damian Stichel, Julian Gutekunst, Adriana Pitea, Steen Sass, Francisco J Sanchez-Rivera, Justo L Bermejo, et al. Epigenetically regulated chromosome 14q32 miRNA cluster induces metastasis and predicts poor prognosis in lung adenocarcinoma patients. Molecular Cancer Research, 2018.

Kotryna Seip, Kjetil Jorgensen, Marco Vincent Haselager, Marco Albrecht, Mads Haugland Haugen, Eivind Valen Egeland, Philippe Lucarelli, Olav Engebraaten, Thomas Sauter, Gunhild Mari Molandsmo, et al. Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. Cancer letters, 2018.

Marco Albrecht, Giuseppe Sciume, Francesca Maria Bosisio, Dagmar Kulms, and Thomas Sauter. Stroma oriented tissue modelling with a
micro-anatomical allocation of mechanical features using virtual rheometry. Planned for: Biomechanics and Modeling in Mechanobiology. (In Preparation)

Marco Albrecht, Yuri Kogan, Philippe Lucarelli, and Thomas Sauter. Systems pharmacology of dabrafenib metabolism: drug interaction, CYP3A4 enzyme induction, and e ect loss in hydrogels. Planned for: Nature Systems Biology and Applications. (In Preparation)

Marco Albrecht, Sebastien De Landtsheer, Philippe Lucarelli, Ines Mueller, Dagmar Kulms, and Thomas Sauter. Systems Biology approaches and computational models for cutaneous melanoma. Planned for: Pigment Cell & Melanoma Research. (In Preparation)

Kah-Tong Seow

PhD Bioinformatics

Lead Software Engineer
Software Developer C# / .Net
& Bioinformatician

About Kah-Tong Seow

Kah-Tong Seow is an experienced Translational Data Science Professional with over 20 years of customer centric experience in consulting bioinformatics and systems biology in drug discovery, personalized medicine from academic institutes to pharma industry and EU Horizon 2020 projects. Through 3 years as founder & program director conducting wearable /IoT/digital health research at a Frankfurt community health centre (FHO), he gained valuable experience on how digital health technology could lead to patient empowerment. This unique insight is critical for developing cross-platform mobile apps, cloud computing applications, business models, and data science strategies that will deliver digital health device enabled platform technologies for precision medicine.

About Marco Albrecht

Marco Albrecht is a Biosystems Engineer, who is passionate about combining natural science disciplines with the power of mathematics.

He was interdisciplinary trained in molecular biology, system theory, control engineering, and modelling from the first semester at the Otto-von-Guericke University in Magdeburg.  Magdeburg is a European hub for bottom-up modelling and harbours the Max-Planck Institute for the Dynamic of Complex Technical Systems.

Marco Albrecht has not only worked in four different hospital wards at an early age but also in several high-tech life-science start-ups and research incubators such as GenDx in the Netherlands, Optimata in Israel and BioMed X in Heidelberg as well as in several research groups such as the experimental dermatology group at the TU Dresden and the porous media department at the University of Bordeaux.

His Master´s thesis at the University of Heidelberg was on identifying differentially expressed features in transcriptome dynamics, and his dissertation at the University of Luxembourg was on mathematical histopathology and systems pharmacology of melanoma. Marco Albrecht reached in all research projects the highest possible grades and was funded by the prestigious EU Marie Skłodowska-Curie research grant.

Marco Albrecht brings substantial experience in modelling tissue physiology, systems biology and analysing omics-data to esqLABS and will act as QSP-platform developer. His first project will be in precision medicine for patients in intensive care units.

List of Publications:

Peer Reviewed Journal Articles

Marco Albrecht, Giuseppe Sciume, Philippe Lucarelli, and Thomas Sauter. Thermodynamically constrained averaging theory for cancer growth modelling. IFAC-PapersOnLine, 49(26):289{294, 2016.

Marco Albrecht, Damian Stichel, Benedikt Muller, Ruth Merkle, Carsten Sticht, Norbert Gretz, Ursula Klingmuller, Kai Breuhahn, and Franziska Matthaus. TTCA: an R package for the identi cation of di erentially expressed genes in time course microarray data. BMC bioinformatics, 18(1):33, 2017.

Margarita Gonzalez-Vallinas, Manuel Rodriguez-Paredes, Marco Albrecht, Carsten Sticht, Damian Stichel, Julian Gutekunst, Adriana Pitea, Steen Sass, Francisco J Sanchez-Rivera, Justo L Bermejo, et al. Epigenetically regulated chromosome 14q32 miRNA cluster induces metastasis and predicts poor prognosis in lung adenocarcinoma patients. Molecular Cancer Research, 2018.

Kotryna Seip, Kjetil Jorgensen, Marco Vincent Haselager, Marco Albrecht, Mads Haugland Haugen, Eivind Valen Egeland, Philippe Lucarelli, Olav Engebraaten, Thomas Sauter, Gunhild Mari Molandsmo, et al. Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. Cancer letters, 2018.

Marco Albrecht, Giuseppe Sciume, Francesca Maria Bosisio, Dagmar Kulms, and Thomas Sauter. Stroma oriented tissue modelling with a
micro-anatomical allocation of mechanical features using virtual rheometry. Planned for: Biomechanics and Modeling in Mechanobiology. (In Preparation)

Marco Albrecht, Yuri Kogan, Philippe Lucarelli, and Thomas Sauter. Systems pharmacology of dabrafenib metabolism: drug interaction, CYP3A4 enzyme induction, and e ect loss in hydrogels. Planned for: Nature Systems Biology and Applications. (In Preparation)

Marco Albrecht, Sebastien De Landtsheer, Philippe Lucarelli, Ines Mueller, Dagmar Kulms, and Thomas Sauter. Systems Biology approaches and computational models for cutaneous melanoma. Planned for: Pigment Cell & Melanoma Research. (In Preparation)

About Kah-Tong Seow

Kah-Tong Seow is an experienced Translational Data Science Professional with over 20 years of customer centric experience in consulting bioinformatics and systems biology in drug discovery, personalized medicine from academic institutes to pharma industry and EU Horizon 2020 projects. Through 3 years as founder & program director conducting wearable /IoT/digital health research at a Frankfurt community health centre (FHO), he gained valuable experience on how digital health technology could lead to patient empowerment. This unique insight is critical for developing cross-platform mobile apps, cloud computing applications, business models, and data science strategies that will deliver digital health device enabled platform technologies for precision medicine.

Vanessa Baier

MSc. Bioinformatics

Consultant PBPK Modeling
Bioinformatician &
Expert IVIVE and DMPK

N. N. (could be you)

PhD / MSc. /  Genius

Consultant PBPK/QSP
Senior Scientist M&S
& R-Enthusiast

Vanessa Baier

MSc. Bioinformatics

Consultant PBPK Modeling
Bioinformatician &
Expert IVIVE and DMPK

About Vanessa Baier

Vanessa is bioinformatician by training, with a focus on computational modeling in the field of systems biology/systems pharmacology. She has experience with lab data management tools, Bayesian population PBPK techniques, and the contextualization of in vitro data and mechanistic PBPK models. Her main area at esqLABS lies in vitro/in vivo extrapolation and toxicity modeling within PBPK QSP.

Vanessa studied computer science at TU Braunschweig and Bioinformatics at Goethe University Frankfurt. After an internship at Sanofi, she completed her master thesis at Bayer in the group of Complex Systems Modeling / Applied Mathematics. She then joined the group of Lars Kuepfer at RWTH Aachen University for working on her PhD.

List of Publications:

Peer Reviewed Journal Articles

Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob. Agents Chemother. 2016; 60(10):6134–45.

Cordes H, Thiel C, Baier V, Blank LM, Kuepfer L. Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation. npj Systems Biology and Applications 2018; 4(1):10.

Kuepfer L, Clayton O, Thiel C, Cordes H, Nudischer R, Blank LM et al. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. Archives of Toxicology 2017.

Thiel C, Cordes H, Baier V, Blank LM, Kuepfer L. Multiscale modeling reveals inhibitory and stimulatory effects of caffeine on acetaminophen-induced toxicity in humans. CPT Pharmacometrics Syst Pharmacol 2017; 6(2):136–46.

Thiel C, Cordes H, Fabbri L, Aschmann HE, Baier V, Smit I et al. A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations. PLoS Comput Biol 2017; 13(2):e1005280.
Thiel C, Smit I, Baier V, Cordes H, Fabry B, Blank LM et al. Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations. npj Systems Biology and Applications 2018; 4(1):28.

Conference Posters

Baier, V., Thiel, C., Cordes, H., Blank, L. M., Kuepfer, L. Developing a physiology-based model of the bile acid metabolism in men. Population Approach Group Europe (PAGE) meeting 2018, Montreux, Switzerland

N. N. (could be you)

PhD / MSc. /  Genius

Consultant PBPK/QSP
Senior Scientist M&S
& R-Enthusiast

About Vanessa Baier

Vanessa is bioinformatician by training, with a focus on computational modeling in the field of systems biology/systems pharmacology. She has experience with lab data management tools, Bayesian population PBPK techniques, and the contextualization of in vitro data and mechanistic PBPK models. Her main area at esqLABS lies in vitro/in vivo extrapolation and toxicity modeling within PBPK QSP.

Vanessa studied computer science at TU Braunschweig and Bioinformatics at Goethe University Frankfurt. After an internship at Sanofi, she completed her master thesis at Bayer in the group of Complex Systems Modeling / Applied Mathematics. She then joined the group of Lars Kuepfer at RWTH Aachen University for working on her PhD.

List of Publications:

Peer Reviewed Journal Articles

Cordes H, Thiel C, Aschmann HE, Baier V, Blank LM, Kuepfer L. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy. Antimicrob. Agents Chemother. 2016; 60(10):6134–45.

Cordes H, Thiel C, Baier V, Blank LM, Kuepfer L. Integration of genome-scale metabolic networks into whole-body PBPK models shows phenotype-specific cases of drug-induced metabolic perturbation. npj Systems Biology and Applications 2018; 4(1):10.

Kuepfer L, Clayton O, Thiel C, Cordes H, Nudischer R, Blank LM et al. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. Archives of Toxicology 2017.

Thiel C, Cordes H, Baier V, Blank LM, Kuepfer L. Multiscale modeling reveals inhibitory and stimulatory effects of caffeine on acetaminophen-induced toxicity in humans. CPT Pharmacometrics Syst Pharmacol 2017; 6(2):136–46.

Thiel C, Cordes H, Fabbri L, Aschmann HE, Baier V, Smit I et al. A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations. PLoS Comput Biol 2017; 13(2):e1005280.
Thiel C, Smit I, Baier V, Cordes H, Fabry B, Blank LM et al. Using quantitative systems pharmacology to evaluate the drug efficacy of COX-2 and 5-LOX inhibitors in therapeutic situations. npj Systems Biology and Applications 2018; 4(1):28.

Conference Posters

Baier, V., Thiel, C., Cordes, H., Blank, L. M., Kuepfer, L. Developing a physiology-based model of the bile acid metabolism in men. Population Approach Group Europe (PAGE) meeting 2018, Montreux, Switzerland

Jobs at esqLABS

We always look for exceptional talent and offer competitive conditions.

Interested applicants should send their CV to Stephan Schaller (stephan.schaller@esqLABS.com)

Get in touch now

Contact

esqLABS GmbH | Hambierich 34 | 26683 Saterland | Germany
Tel. +49 151 / 58559070 | info@esqLABS.com